Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26559294 | 0.79 | POLB (0.35) | POLBGAAGFERALDH1A1CYP1A2 | |
| SCHEMBL25555727 | 0.75 | POLB (0.61) | POLBGAAGFERCYP3A4TSHR | |
| SCHEMBL25725280 | 0.73 | POLB (0.59) | POLBGAAGFERCYP3A4TSHR | |
| SCHEMBL3649606 | 0.73 | POLB (0.59) | POLBGAAGFERCYP3A4TSHR | |
| SCHEMBL30335334 | 0.73 | JAK2 (0.35) | — | |
| SCHEMBL22236082 | 0.73 | ALDH1A1 (0.36) | GAATSHRALDH1A1 | |
| SCHEMBL9324230 | 0.71 | POLB (0.57) | POLBGAAGFERCYP3A4TSHR | |
| SCHEMBL15577019 | 0.71 | CHRNB2 (0.36) | — | |
| SCHEMBL9819248 | 0.71 | CYP3A4 (0.41) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL13569777 | 0.70 | CYP3A4 (0.41) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-4194449-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-20220089540-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2022-03-24 | — | — | US | disclosed |
| EP-3911309-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | Board Of Trustees Of Michigan State University (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150668-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | C9, CFB, C5 | POLB 1165/4885GAA 2688/4885GFER 628/4885 |
| US-20220089540-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | PDCD1, CD274, PDCD1LG2 | POLB 1211/4885GAA 2429/4885GFER 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.